| Name | Title | Contact Details |
|---|
Antibe Therapeutics develops safer medications for chronic pain and inflammation. Today, physicians and consumers rely principally on non-steroidal anti-inflammatory drugs (NSAIDs), a $12 billion category of medications that includes brands like Advil, Aleve, Motrin, Celebrex, Voltaren and Aspirin. While effective, NSAIDs can cause gastrointestinal damage and bleeding. To address this serious medical need, Antibe has patented a technology for linking NSAID molecules to hydrogen sulfide molecules. More than a decade of academic and applied research has demonstrated that hydrogen sulfide, when appropriately delivered, can protect the gastrointestinal tract and enhance the anti-inflammatory effectiveness of today’s NSAIDs. Beginning with its IPO in mid-2013, Antibe has raised more than $10 million and initiated human clinical trials of its first drug, aimed at mild to moderate pain.
Light House Ministries is a Lake Bluff, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We are industry-leading experts in Bio Convergence. By combining the power of biology, engineering and computer science, we create the future of health. We extend the boundaries of what`s possible to give people better and healthier lives. Products from the BICO Group are trusted by more than 2,00 laboratories, including ones at all the top 20 pharmaceutical companies, are being used in more than 60 countries, and have been cited in more than 1800 publications. BICO is creating the future of health. Visit bico.com to learn more. BICO is listed on the Nasdaq Stockholm Main Market under BICO.
Pinetree Therapeutics is an award-winning, pre-clinical stage biotechnology company based in Cambridge, Massachusetts. We are dedicated to finding solutions for unmet medical need, such as drug resistance and tumor recurrence, in targeted therapy by degradation of disease-causing proteins with AbReptorTM platform. Novel degrader drugs have been exciting scientific field, due to its distinct mechanism of action (removal of disease-causing protein). AbReptorTM was developed for targeted degradation on membrane bound and extracellular proteins causing diseases. Receptor tyrosine kinase (RTK) and non-RTK inhibitors have made huge progress in the past few years, but their application is limited due to specificity, drug resistance, and on-target toxicity. Our platform`s RTK degraders promise to redefine their distinctive mutation-agnostic properties, differing from existing RTK therapeutics field. With the pre-clinical animal study, our lead molecule demonstrated on-target degradation, mutation agnostic anti-tumor effect, and potent anti-tumor effect in RTK inhibitor resistant tumor. Surprisingly, no signs of toxicity were found in rodent and cynomolgus monkey. Furthermore, it would unluck full potential to solve limitation of RTK and non-RTK therapeutics. Immune checkpoint inhibitors (ICIs) field made an initial breakthrough with poor response rate, high toxicity profiles, and exhausted poor clinical outcome. Our platform has full potential to solve the current problem of immune checkpoint inhibitors (ICIs), PD-(L)1 inhibitors. Our PD-(L)1 degrader is the first ever in-class to demonstrate enhanced anti-tumor immunity in pre-clinical animal studies. Pinetree Therapeutics` lead molecule is in pre-clinical IND stage, and we are committed to expanding our platforms to other target proteins, such as RTKs, non-RTKs, and ICIs. We believe our platform has the potential to transform the field of medicine and revolutionize the treatment of cancer and other diseases.
Finishing Touch Salon is a Waterbury, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.